Quince Therapeutics announces first patient dosed in Phase 3 trial of EryDex

Quince Therapeutics announced that the first patient has been dosed in the company’s Phase 3 NEAT clinical trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia. This pivotal Phase 3 study will be conducted under a Special Protocol Assessment agreement with the U.S. Food & Drug Administration. “The initiation of our pivotal Phase 3 NEAT study is a major milestone for Quince, and an opportunity for patients living with the devastating effects of Ataxia-Telangiectasia to participate in research seeking to identify a beneficial therapeutic solution,” said Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer. “There are currently no approved therapeutic treatments in any global market for this rare pediatric disease, and our primary corporate objective is to change that for patients with A-T and their families.”